Triamcinolone Acetonide Nasal Spray Rx
Generic Name and Formulations:
Triamcinolone acetonide 55mcg/spray; aqueous nasal spray.
Various generic manufacturers
Indications for Triamcinolone Acetonide Nasal Spray:
Seasonal and perennial allergic rhinitis.
2 sprays in each nostril once daily. Reduce dose as condition improves.
<2yrs: not established. 2–5yrs: 1 spray in each nostril once daily. 6–12yrs: 1 spray in each nostril once daily; max 2 sprays in each nostril once daily. Reduce dose as condition improves.
Maintain regular regimen. Respiratory tract tuberculosis. Infections (eg, ocular herpes simplex). If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. Avoid use in patients with recent nasal ulcers, surgery, or trauma. Reevaluate if no improvement in 3 weeks. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with topical corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, depression). Monitor for growth suppression in children. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually), changes in vision or increased intraocular pressure, and candida infection or other nasal mucosal changes. Avoid eyes. Pregnancy (Cat.C). Nursing mothers.
Pharyngitis, epistaxis, flu syndrome, cough increased, bronchitis, headache, pharyngolaryngeal pain, nasopharyngitis, abdominal upper pain, GI upset; glaucoma/cataracts, impaired wound healing, reduced growth velocity in children.
Nasal spray—16.5g (120 sprays)
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies